Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Language
Publication year range
1.
J Fr Ophtalmol ; 46(1): 41-48, 2023 Jan.
Article in French | MEDLINE | ID: mdl-36494264

ABSTRACT

INTRODUCTION: Intravitreal injections (IVT) of a drug aim to rapidly obtain effective concentrations greater than those that would be obtained by a periocular or intravenous injection. The objective of the present study is to demonstrate the contribution of IVT in the treatment of pathologies of the posterior segment of the eye. METHODOLOGY: We conducted a 21-month ambidirectional observational study from January 1, 2020, to September 30, 2021. We included by nonprobability sampling all consenting patients admitted for IVT at IOTA Teaching Hospital. RESULTS: During our study, 201 patients were collected out of 30 739 patients seen in consultation. The hospital frequency of IVT was 0.65%. There were 111 women and 90 men. The M/F ratio was 0.82. The number of patients who received IVT antibiotics was 135. Anti-VEGF was injected in 64 patients. Two patients received IVT corticosteroids. Complications frequently encountered were pain at upon injection (94.03%), IOP spike (11.94%) and cataract (7.46%). In our sample, we observed an improvement in visual acuity in 56.21% of cases and a reduction in macular edema in 45.16% of cases. DISCUSSION: The contribution of IVT in the treatment of vitreoretinal diseases is extraordinary. Rigorous observation of aseptic technique and good practices protects against infectious complications. CONCLUSION: IVT has allowed us to effectively treat various diseases of the vitreous and retina. IVT is a simple procedure, but it must be performed with the same aseptic technique as surgical procedures.


Subject(s)
Diabetic Retinopathy , Glucocorticoids , Male , Humans , Female , Glucocorticoids/therapeutic use , Triamcinolone Acetonide/adverse effects , Bevacizumab , Intravitreal Injections , Angiogenesis Inhibitors , Vascular Endothelial Growth Factor A , Diabetic Retinopathy/drug therapy , Treatment Outcome , Hospitals, Teaching
2.
Med. Afr. noire (En ligne) ; 66(10): 529-534, 2019.
Article in French | AIM (Africa) | ID: biblio-1266329

ABSTRACT

Introduction : L'anophtalmie congénitale est l'absence clinique de l'œil à la naissance. Elle résulte de l'absence de développement ou de la régression de la vésicule optique primaire pendant la vie embryonnaire. C'est une anomalie rare et qui peut être isolée ou associée à des d'autres malformations congénitales oculaires ou générales. Observation : Nous rapportons un cas d'anophtalmie congénitale, chez un nouveau-né âgé de 4 heures. Le bilan prénatal était sans particularité. L'examen ophtalmologique a objectivé une anophtalmie unilatérale, confirmée à l'échographie oculaire. Discussion : L'anophtalmie congénitale est une malformation rare. Elle peut être isolée ou intégrée à un syndrome poly-malformatif. Le tableau clinique est le plus souvent unilatéral. Le diagnostic est essentiellement clinique et confirmé par l'échographie oculaire. Les étiologies sont variées, représentées par les aberrations chromosomiques, les mutations génétiques, les intoxications et les infections acquises au cours de la grossesse. Conclusion : La découverte d'une anophtalmie congénitale impose un bilan exhaustif en vue de rechercher l'étiologie. Le soutien psychologique des parents demeure également un axe important de la prise en charge


Subject(s)
Anophthalmos , Anophthalmos/diagnosis , Anophthalmos/etiology , Infant, Newborn , Mali
SELECTION OF CITATIONS
SEARCH DETAIL
...